Outcome of enzyme replacement therapy in children with Gaucher disease: The Egyptian experience

Gaucher disease is the most prevalent lysosomal storage diseases which results from inherited deficiency in the glucocerebrosidase enzyme. Three main clinical forms have been described: type I non-neuropathic, type II acute neuropathic and type III subacute neuropathic. Although it is panethnic dise...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:The Egyptian journal of medical human genetics 2011-05, Vol.12 (1), p.9-14
Hauptverfasser: Khalifa, Ahmed S., Tantawy, Azza A., Shawky, Rabah M., Monir, Eman, Elsayed, Solaf M., Fateen, Ekram, Cooper, Alan
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 14
container_issue 1
container_start_page 9
container_title The Egyptian journal of medical human genetics
container_volume 12
creator Khalifa, Ahmed S.
Tantawy, Azza A.
Shawky, Rabah M.
Monir, Eman
Elsayed, Solaf M.
Fateen, Ekram
Cooper, Alan
description Gaucher disease is the most prevalent lysosomal storage diseases which results from inherited deficiency in the glucocerebrosidase enzyme. Three main clinical forms have been described: type I non-neuropathic, type II acute neuropathic and type III subacute neuropathic. Although it is panethnic disease, its presentation has some ethnic specific characteristics. In this work, we present specific characteristics as well as our experience in diagnosing and managing a group of Egyptian patients with this disease. The study included 48 patients with Gaucher disease attending Children’s Hospital, Ain Shams University. The recombinant enzyme imiglucerase (cerezyme) was given in a dose of 60 U/kg/2 weeks. Haemoglobin, platelet count, plasma chitotriosidase, and abdominal ultrasound were assessed before starting therapy and every 6 months. Molecular analysis was done to 23 patients. At presentation, the mean age was 2.54 ± 3.8 years. Ten patients (20.8%) had type I, 6 had type II (12.5%) and 26 had type III Gaucher disease (66.7%). The commonest genotype was homozygous L444P which was present in 13 patients (56.5%) followed by homozygous N370S; found in three patients (13.04%). Follow up after enzyme replacement therapy revealed a significant increase in weight and height, haemoglobin level and platelet count and slow reduction in the liver span and spleen length. Bone manifestations showed slow but complete improvement while neurological and respiratory manifestations were partially ameliorated with individual variations. To conclude, since most of Egyptian children with GD have type III disease and L444P/L444P genotype, a minimum dose of 60 U/kg/2 weeks should be maintained until adulthood. Higher doses started at an early age may delay the progression of neurological symptoms. Pulmonary involvement is not rare in Egyptian patients and may respond to dose increase or dose fractionation. Cardiovascular and renal involvement should be further studied in our population.
doi_str_mv 10.1016/j.ejmhg.2011.02.008
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_923248875</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1110863011000097</els_id><sourcerecordid>2593974281</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3128-4aa911c5ad0cb1a188c09e3fa57198869e7cee944b134930fdbcb452de97ba913</originalsourceid><addsrcrecordid>eNp9kE9r3DAQxUVoodukn6AERO92ZiR5LQV6KCH_IJBLehayPI5ldm1H8jbdfvoq2ZBjTjPw3m-G9xj7jlAi4PpsKGnY9o-lAMQSRAmgj9hKgIFCKIWf2AoRodBrCV_Y15QGgHUla7Vi9n63-GlLfOo4jf_2eYs0b5ynLY0LX3qKbt7zMHLfh00baeTPYen5tdv5rPE2JHKJzvlDT_zycT8vwY2c_s4UA42eTtjnzm0SfXubx-z31eXDxU1xd399e_HrrvAShS6UcwbRV64F36BDrT0Ykp2rajRarw3Vnsgo1aBURkLXNr5RlWjJ1E1G5TH7cbg7x-lpR2mxw7SLY35pjZBCaV1X2SQPJh-nlCJ1do5h6-LeItiXIu1gX4u0L0VaEDYXmanTA0XZSp17h6QGoeqs_3zTc74_gaJN_jV7GyL5xbZT-PD-f4jfh38</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>923248875</pqid></control><display><type>article</type><title>Outcome of enzyme replacement therapy in children with Gaucher disease: The Egyptian experience</title><source>DOAJ Directory of Open Access Journals</source><source>African Journals Online (Open Access)</source><source>Access via ScienceDirect (Elsevier)</source><source>EZB-FREE-00999 freely available EZB journals</source><creator>Khalifa, Ahmed S. ; Tantawy, Azza A. ; Shawky, Rabah M. ; Monir, Eman ; Elsayed, Solaf M. ; Fateen, Ekram ; Cooper, Alan</creator><creatorcontrib>Khalifa, Ahmed S. ; Tantawy, Azza A. ; Shawky, Rabah M. ; Monir, Eman ; Elsayed, Solaf M. ; Fateen, Ekram ; Cooper, Alan</creatorcontrib><description>Gaucher disease is the most prevalent lysosomal storage diseases which results from inherited deficiency in the glucocerebrosidase enzyme. Three main clinical forms have been described: type I non-neuropathic, type II acute neuropathic and type III subacute neuropathic. Although it is panethnic disease, its presentation has some ethnic specific characteristics. In this work, we present specific characteristics as well as our experience in diagnosing and managing a group of Egyptian patients with this disease. The study included 48 patients with Gaucher disease attending Children’s Hospital, Ain Shams University. The recombinant enzyme imiglucerase (cerezyme) was given in a dose of 60 U/kg/2 weeks. Haemoglobin, platelet count, plasma chitotriosidase, and abdominal ultrasound were assessed before starting therapy and every 6 months. Molecular analysis was done to 23 patients. At presentation, the mean age was 2.54 ± 3.8 years. Ten patients (20.8%) had type I, 6 had type II (12.5%) and 26 had type III Gaucher disease (66.7%). The commonest genotype was homozygous L444P which was present in 13 patients (56.5%) followed by homozygous N370S; found in three patients (13.04%). Follow up after enzyme replacement therapy revealed a significant increase in weight and height, haemoglobin level and platelet count and slow reduction in the liver span and spleen length. Bone manifestations showed slow but complete improvement while neurological and respiratory manifestations were partially ameliorated with individual variations. To conclude, since most of Egyptian children with GD have type III disease and L444P/L444P genotype, a minimum dose of 60 U/kg/2 weeks should be maintained until adulthood. Higher doses started at an early age may delay the progression of neurological symptoms. Pulmonary involvement is not rare in Egyptian patients and may respond to dose increase or dose fractionation. Cardiovascular and renal involvement should be further studied in our population.</description><identifier>ISSN: 1110-8630</identifier><identifier>EISSN: 2090-2441</identifier><identifier>DOI: 10.1016/j.ejmhg.2011.02.008</identifier><language>eng</language><publisher>Cairo, Egypt: Elsevier B.V</publisher><subject>Chitotriosidase ; Enzymes ; Gaucher disease ; Genetic disorders in children ; Genotype ; Lysosomal storage disease ; Lysosomal storage diseases ; Recombinent enzyme ; Therapeutic use ; Treatment ; الأطفال ; الأنزيمات ; الاضطرابات الوراثية</subject><ispartof>The Egyptian journal of medical human genetics, 2011-05, Vol.12 (1), p.9-14</ispartof><rights>2011</rights><rights>Copyright Egyptian Society of Medical Human Genetics 2011</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3128-4aa911c5ad0cb1a188c09e3fa57198869e7cee944b134930fdbcb452de97ba913</citedby><cites>FETCH-LOGICAL-c3128-4aa911c5ad0cb1a188c09e3fa57198869e7cee944b134930fdbcb452de97ba913</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.ejmhg.2011.02.008$$EHTML$$P50$$Gelsevier$$Hfree_for_read</linktohtml><link.rule.ids>314,780,784,864,3550,27924,27925,45995</link.rule.ids></links><search><creatorcontrib>Khalifa, Ahmed S.</creatorcontrib><creatorcontrib>Tantawy, Azza A.</creatorcontrib><creatorcontrib>Shawky, Rabah M.</creatorcontrib><creatorcontrib>Monir, Eman</creatorcontrib><creatorcontrib>Elsayed, Solaf M.</creatorcontrib><creatorcontrib>Fateen, Ekram</creatorcontrib><creatorcontrib>Cooper, Alan</creatorcontrib><title>Outcome of enzyme replacement therapy in children with Gaucher disease: The Egyptian experience</title><title>The Egyptian journal of medical human genetics</title><description>Gaucher disease is the most prevalent lysosomal storage diseases which results from inherited deficiency in the glucocerebrosidase enzyme. Three main clinical forms have been described: type I non-neuropathic, type II acute neuropathic and type III subacute neuropathic. Although it is panethnic disease, its presentation has some ethnic specific characteristics. In this work, we present specific characteristics as well as our experience in diagnosing and managing a group of Egyptian patients with this disease. The study included 48 patients with Gaucher disease attending Children’s Hospital, Ain Shams University. The recombinant enzyme imiglucerase (cerezyme) was given in a dose of 60 U/kg/2 weeks. Haemoglobin, platelet count, plasma chitotriosidase, and abdominal ultrasound were assessed before starting therapy and every 6 months. Molecular analysis was done to 23 patients. At presentation, the mean age was 2.54 ± 3.8 years. Ten patients (20.8%) had type I, 6 had type II (12.5%) and 26 had type III Gaucher disease (66.7%). The commonest genotype was homozygous L444P which was present in 13 patients (56.5%) followed by homozygous N370S; found in three patients (13.04%). Follow up after enzyme replacement therapy revealed a significant increase in weight and height, haemoglobin level and platelet count and slow reduction in the liver span and spleen length. Bone manifestations showed slow but complete improvement while neurological and respiratory manifestations were partially ameliorated with individual variations. To conclude, since most of Egyptian children with GD have type III disease and L444P/L444P genotype, a minimum dose of 60 U/kg/2 weeks should be maintained until adulthood. Higher doses started at an early age may delay the progression of neurological symptoms. Pulmonary involvement is not rare in Egyptian patients and may respond to dose increase or dose fractionation. Cardiovascular and renal involvement should be further studied in our population.</description><subject>Chitotriosidase</subject><subject>Enzymes</subject><subject>Gaucher disease</subject><subject>Genetic disorders in children</subject><subject>Genotype</subject><subject>Lysosomal storage disease</subject><subject>Lysosomal storage diseases</subject><subject>Recombinent enzyme</subject><subject>Therapeutic use</subject><subject>Treatment</subject><subject>الأطفال</subject><subject>الأنزيمات</subject><subject>الاضطرابات الوراثية</subject><issn>1110-8630</issn><issn>2090-2441</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2011</creationdate><recordtype>article</recordtype><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><recordid>eNp9kE9r3DAQxUVoodukn6AERO92ZiR5LQV6KCH_IJBLehayPI5ldm1H8jbdfvoq2ZBjTjPw3m-G9xj7jlAi4PpsKGnY9o-lAMQSRAmgj9hKgIFCKIWf2AoRodBrCV_Y15QGgHUla7Vi9n63-GlLfOo4jf_2eYs0b5ynLY0LX3qKbt7zMHLfh00baeTPYen5tdv5rPE2JHKJzvlDT_zycT8vwY2c_s4UA42eTtjnzm0SfXubx-z31eXDxU1xd399e_HrrvAShS6UcwbRV64F36BDrT0Ykp2rajRarw3Vnsgo1aBURkLXNr5RlWjJ1E1G5TH7cbg7x-lpR2mxw7SLY35pjZBCaV1X2SQPJh-nlCJ1do5h6-LeItiXIu1gX4u0L0VaEDYXmanTA0XZSp17h6QGoeqs_3zTc74_gaJN_jV7GyL5xbZT-PD-f4jfh38</recordid><startdate>201105</startdate><enddate>201105</enddate><creator>Khalifa, Ahmed S.</creator><creator>Tantawy, Azza A.</creator><creator>Shawky, Rabah M.</creator><creator>Monir, Eman</creator><creator>Elsayed, Solaf M.</creator><creator>Fateen, Ekram</creator><creator>Cooper, Alan</creator><general>Elsevier B.V</general><general>Egyptian Society of Human Genetics</general><general>Springer Nature B.V</general><scope>6I.</scope><scope>AAFTH</scope><scope>ADJCN</scope><scope>AEEDL</scope><scope>AFFIF</scope><scope>AHFXO</scope><scope>AHHHR</scope><scope>AHQOB</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>CWDGH</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M7P</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope></search><sort><creationdate>201105</creationdate><title>Outcome of enzyme replacement therapy in children with Gaucher disease: The Egyptian experience</title><author>Khalifa, Ahmed S. ; Tantawy, Azza A. ; Shawky, Rabah M. ; Monir, Eman ; Elsayed, Solaf M. ; Fateen, Ekram ; Cooper, Alan</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3128-4aa911c5ad0cb1a188c09e3fa57198869e7cee944b134930fdbcb452de97ba913</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2011</creationdate><topic>Chitotriosidase</topic><topic>Enzymes</topic><topic>Gaucher disease</topic><topic>Genetic disorders in children</topic><topic>Genotype</topic><topic>Lysosomal storage disease</topic><topic>Lysosomal storage diseases</topic><topic>Recombinent enzyme</topic><topic>Therapeutic use</topic><topic>Treatment</topic><topic>الأطفال</topic><topic>الأنزيمات</topic><topic>الاضطرابات الوراثية</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Khalifa, Ahmed S.</creatorcontrib><creatorcontrib>Tantawy, Azza A.</creatorcontrib><creatorcontrib>Shawky, Rabah M.</creatorcontrib><creatorcontrib>Monir, Eman</creatorcontrib><creatorcontrib>Elsayed, Solaf M.</creatorcontrib><creatorcontrib>Fateen, Ekram</creatorcontrib><creatorcontrib>Cooper, Alan</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>الدوريات العلمية والإحصائية - e-Marefa Academic and Statistical Periodicals</collection><collection>قاعدة الخدمة الاجتماعية والعمل الخيري والأوقاف - e-Marefa Social &amp; Charitable Work and Endowments</collection><collection>قاعدة دراسات المرأة - e-Marefa Women Studies</collection><collection>معرفة - المحتوى العربي الأكاديمي المتكامل - e-Marefa Academic Complete</collection><collection>دراسات الشرق الأوسط - e-Marefa Middle Eastern Studies</collection><collection>الشؤون الدولية والعربية - e-Marefa International &amp; Arab Affairs</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>Middle East &amp; Africa Database</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Biological Science Database</collection><collection>Access via ProQuest (Open Access)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><jtitle>The Egyptian journal of medical human genetics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Khalifa, Ahmed S.</au><au>Tantawy, Azza A.</au><au>Shawky, Rabah M.</au><au>Monir, Eman</au><au>Elsayed, Solaf M.</au><au>Fateen, Ekram</au><au>Cooper, Alan</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Outcome of enzyme replacement therapy in children with Gaucher disease: The Egyptian experience</atitle><jtitle>The Egyptian journal of medical human genetics</jtitle><date>2011-05</date><risdate>2011</risdate><volume>12</volume><issue>1</issue><spage>9</spage><epage>14</epage><pages>9-14</pages><issn>1110-8630</issn><eissn>2090-2441</eissn><abstract>Gaucher disease is the most prevalent lysosomal storage diseases which results from inherited deficiency in the glucocerebrosidase enzyme. Three main clinical forms have been described: type I non-neuropathic, type II acute neuropathic and type III subacute neuropathic. Although it is panethnic disease, its presentation has some ethnic specific characteristics. In this work, we present specific characteristics as well as our experience in diagnosing and managing a group of Egyptian patients with this disease. The study included 48 patients with Gaucher disease attending Children’s Hospital, Ain Shams University. The recombinant enzyme imiglucerase (cerezyme) was given in a dose of 60 U/kg/2 weeks. Haemoglobin, platelet count, plasma chitotriosidase, and abdominal ultrasound were assessed before starting therapy and every 6 months. Molecular analysis was done to 23 patients. At presentation, the mean age was 2.54 ± 3.8 years. Ten patients (20.8%) had type I, 6 had type II (12.5%) and 26 had type III Gaucher disease (66.7%). The commonest genotype was homozygous L444P which was present in 13 patients (56.5%) followed by homozygous N370S; found in three patients (13.04%). Follow up after enzyme replacement therapy revealed a significant increase in weight and height, haemoglobin level and platelet count and slow reduction in the liver span and spleen length. Bone manifestations showed slow but complete improvement while neurological and respiratory manifestations were partially ameliorated with individual variations. To conclude, since most of Egyptian children with GD have type III disease and L444P/L444P genotype, a minimum dose of 60 U/kg/2 weeks should be maintained until adulthood. Higher doses started at an early age may delay the progression of neurological symptoms. Pulmonary involvement is not rare in Egyptian patients and may respond to dose increase or dose fractionation. Cardiovascular and renal involvement should be further studied in our population.</abstract><cop>Cairo, Egypt</cop><pub>Elsevier B.V</pub><doi>10.1016/j.ejmhg.2011.02.008</doi><tpages>6</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1110-8630
ispartof The Egyptian journal of medical human genetics, 2011-05, Vol.12 (1), p.9-14
issn 1110-8630
2090-2441
language eng
recordid cdi_proquest_journals_923248875
source DOAJ Directory of Open Access Journals; African Journals Online (Open Access); Access via ScienceDirect (Elsevier); EZB-FREE-00999 freely available EZB journals
subjects Chitotriosidase
Enzymes
Gaucher disease
Genetic disorders in children
Genotype
Lysosomal storage disease
Lysosomal storage diseases
Recombinent enzyme
Therapeutic use
Treatment
الأطفال
الأنزيمات
الاضطرابات الوراثية
title Outcome of enzyme replacement therapy in children with Gaucher disease: The Egyptian experience
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-27T17%3A26%3A17IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Outcome%20of%20enzyme%20replacement%20therapy%20in%20children%20with%20Gaucher%20disease:%20The%20Egyptian%20experience&rft.jtitle=The%20Egyptian%20journal%20of%20medical%20human%20genetics&rft.au=Khalifa,%20Ahmed%20S.&rft.date=2011-05&rft.volume=12&rft.issue=1&rft.spage=9&rft.epage=14&rft.pages=9-14&rft.issn=1110-8630&rft.eissn=2090-2441&rft_id=info:doi/10.1016/j.ejmhg.2011.02.008&rft_dat=%3Cproquest_cross%3E2593974281%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=923248875&rft_id=info:pmid/&rft_els_id=S1110863011000097&rfr_iscdi=true